These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 23706974)
1. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD). Song IU; Kim JS; Park IS; Kim YD; Cho HJ; Chung SW; Lee KS Arch Gerontol Geriatr; 2013; 57(3):288-91. PubMed ID: 23706974 [TBL] [Abstract][Full Text] [Related]
3. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Camicioli RM; Bouchard TP; Somerville MJ Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534 [TBL] [Abstract][Full Text] [Related]
4. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893 [TBL] [Abstract][Full Text] [Related]
5. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital. Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818 [TBL] [Abstract][Full Text] [Related]
6. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046 [TBL] [Abstract][Full Text] [Related]
8. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010 [TBL] [Abstract][Full Text] [Related]
9. Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease. Sapkota S; Gee M; Sabino J; Emery D; Camicioli R Mov Disord; 2014 Mar; 29(3):368-74. PubMed ID: 24395213 [TBL] [Abstract][Full Text] [Related]
10. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283 [TBL] [Abstract][Full Text] [Related]
11. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554 [TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306 [TBL] [Abstract][Full Text] [Related]
13. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165 [TBL] [Abstract][Full Text] [Related]
15. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa]. Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319 [TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease. Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422 [TBL] [Abstract][Full Text] [Related]
17. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Toth C; Brown MS; Furtado S; Suchowersky O; Zochodne D Mov Disord; 2008 Oct; 23(13):1850-9. PubMed ID: 18785232 [TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266 [TBL] [Abstract][Full Text] [Related]
19. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Ceravolo R; Cossu G; Bandettini di Poggio M; Santoro L; Barone P; Zibetti M; Frosini D; Nicoletti V; Manganelli F; Iodice R; Picillo M; Merola A; Lopiano L; Paribello A; Manca D; Melis M; Marchese R; Borelli P; Mereu A; Contu P; Abbruzzese G; Bonuccelli U Mov Disord; 2013 Sep; 28(10):1391-7. PubMed ID: 23836370 [TBL] [Abstract][Full Text] [Related]
20. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Hu XW; Qin SM; Li D; Hu LF; Liu CF Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]